(Q37862077)

24 August 2017

1 reference

title

Targeting the human EGFR family in esophagogastric cancer (English)

1 reference

24 August 2017

2

David Cunningham

1 reference

24 August 2017

1

Alicia Okines

1 reference

24 August 2017

Ian Chau

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

5 April 2011

1 reference

Nature Reviews Clinical Oncology

24 August 2017

published in

1 reference

24 August 2017

volume

8

1 reference

24 August 2017

issue

8

1 reference

24 August 2017

page(s)

492-503

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Clinical implications of the mechanism of epidermal growth factor receptor inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Breast cancer: the upgraded role of HER-3 and HER-4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Epidermal growth factor receptor structural alterations in gastric cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Platinum-based chemotherapy plus cetuximab in head and neck cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

A comparison of multimodal therapy and surgery for esophageal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Erlotinib in lung cancer - molecular and clinical predictors of outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

High expression of HER3 is associated with a decreased survival in gastric cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Expression of the c-erbB-3 gene product in gastric cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

The prevalence of PIK3CA mutations in gastric and colon cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.45

HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.

31 March 2020

1 reference

12 December 2020

Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro

1 reference

12 December 2020

Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma

1 reference

12 December 2020

Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas.

1 reference

12 December 2020

Chemotherapy for advanced gastric cancer

1 reference

12 December 2020

Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines.

1 reference

12 December 2020

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions

1 reference

12 December 2020

10.1038/NRCLINONC.2011.45

Identifiers

DOI

1 reference

24 August 2017

1 reference